Urological malignancy after renal transplantation

Besarani, Dler; Cranston, David

doi:10.1111/j.1464-410x.2007.07049.x

Cited by 46 publications

(38 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Overwhelmingly, the major problem in patients with urothelial cancer following renal transplant is that many patients present with advanced disease at diagnosis, and the final treatment outcomes in this group of patients are unfortunately poor. In a review study by Besarani et al [15], chemotherapy treatment with adjustment or cessation of immunosuppressive therapy was found to be marginally beneficial in patients with metastatic disease after renal transplantation.…”

Section: Discussionmentioning

confidence: 97%

Urothelial cancers after renal transplantation

Cox

Colli

2011

Int Urol Nephrol

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 97%

Urothelial cancers after renal transplantation

Cox

Colli

2011

Int Urol Nephrol

View full text Add to dashboard Cite

show abstract

“…However, early diagnosis is necessary to save the graft with limited surgery. 36 We detected the second most common solidorgan tumor as thyroid papillary microcar cinoma in our patients. Two of 4 patients with thyroid carcinoma had metastatic lymph nodes at the time of tumor diagnosis.…”

Section: Eda Yılmaz Akçay Et Al/experimental and Clinical Transplantamentioning

confidence: 51%

Untitled

Akçay

Tepeoğlu²,

Özdemir³

et al. 2016

Exp Clin Transplant

View full text Add to dashboard Cite

Objectives: The aim of this study was to evaluate the incidence of posttransplant malignancy in kidney transplant patients and investigate the clinical and histopathologic features of these patients. Materials and Methods: We retrospectively reviewed information on donor and recipient characteristics, patient and graft survival, and cancer incidence after transplant for 867 kidney transplant patients. Patients with neoplasms prior to transplant were excluded. A follow-up study estimated cancer incidence after transplant. Results: Neoplasms were diagnosed in 59 patients (6.8%), 41 men and 18 women; 22 (37.3%) had skin tumors, 19 (32.2%) had solid tumors, 10 (16.9%) had posttransplant lymphoproliferative disorders, and 8 (13.6%) had Kaposi sarcoma. The mean age at the time of malignant tumor diagnosis was 42.7 ± 13.6 years, and statistically significant differences were found between tumor groups (P < .01). The average latency period between transplant and diagnosis of malignant tumors was 99.8 ± 56.9 months for solid tumors, 78.4 ± 52 months for skin tumors, 64.5 ± 48.8 months for posttransplant lymphoproliferative disorders, and 13.5 ± 8.8 months for Kaposi sarcoma, with significant difference found between tumor groups (P < .01). Ten patients (16.9%) had more than 1 malignant tumor. Eighteen patients died, with a mean time to death of 31.5 ± 22.8 months after tumor diagnosis. A significant positive association was found between survival and the number of tumors (P = .001); 5-year survival after tumor diagnosis was 81% and 40% for patients with 1 malignant tumor and patients with more than 1 malignant tumor, respectively. Conclusions:Malignancy is a common cause of death after renal transplant. Early detection and treatment of posttransplant malignancies is an important challenge. Screening these patients for malignancies posttransplant is crucial, and efforts should be directed to define effective immunosuppressive protocols that are associated with a lower incidence of malignancy.

show abstract

“…A small proportion of these are urological malignancies, of which renal cancer is the most common. 1 Most bladder cancers in transplant recipients are TCC, and the disease follows an aggressive course. 2 An SCC of the bladder in the post-transplant setting has not been reported so far.…”

Section: Discussionmentioning

confidence: 99%

Small cell carcinoma of the bladder in transplant recipients: a report of 2 cases

Katkoori

Cohen

Soloway

et al. 2013

CUAJ

View full text Add to dashboard Cite

Small cell carcinoma (SCC) of the urinary bladder is a rare disease accounting for 0.5% to 0.7% of all primary bladder cancers. Transplant recipients are a special subset of patients with increased risk for various urologic malignancies, including transitional cell carcinoma of the bladder. However, to the best of our knowledge, a SCC of the urinary bladder has not been reported in transplant recipients. We report what we believe are the first 2 reported cases of transplant recipients with SCC of the bladder. Small cell carcinoma was diagnosed 5 years after transplantation in both patients and they died due to metastatic SCC. Our report emphasizes the highly aggressive nature of SCC and also the rapid progression seen in transplant recipients.

show abstract

Urological malignancy after renal transplantation

Cited by 46 publications

References 38 publications

Urothelial cancers after renal transplantation

Urothelial cancers after renal transplantation

Untitled

Small cell carcinoma of the bladder in transplant recipients: a report of 2 cases

Contact Info

Product

Resources

About